Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients: The INFINITI Study

NCT04965935 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04965935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04965935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients: The INFINITI Study
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Completed
Start date
July 15, 2021
Completion date
August 30, 2024
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant recipients, post-transplant diabetes mellitus, type 2 diabetes